Delcath Systems, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on the stock and has a $30.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Swayampakula Ramakanth has given his Buy rating due to a combination of factors, including Delcath’s strong procedure-driven revenue growth and clear visibility into 2026 performance. He highlights that 2025 sales of $85.2M reflected a 140% year-over-year increase in procedures, and management’s floor guidance of at least $100M for 2026, supported by a planned expansion from 28 to 40 active sites, suggests additional upside to current expectations.
Ramakanth also points to upcoming CHOPIN trial publication as a potential catalyst, as it may drive inclusion in NCCN guidelines and further physician adoption of HEPZATO. In addition, he views the company’s ability to sustain a roughly 10% net pricing discount, maintain an ASP around $175K, and generate about $750K in revenue per patient—alongside stable new patient start trends—as reinforcing both pricing power and durable demand, supporting his positive stance on the stock.
In another report released on February 27, Canaccord Genuity also maintained a Buy rating on the stock with a $21.00 price target.